Rigel Pharma downgraded by Cantor Fitzgerald with a new price target

$RIGL
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $RIGL alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $RIGL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RIGL

DatePrice TargetRatingAnalyst
4/3/2023$2.00Neutral
Piper Sandler
6/9/2022Buy → Neutral
Citigroup
6/8/2022$7.00 → $1.00Overweight → Neutral
Piper Sandler
6/8/2022$6.00 → $1.00Overweight → Neutral
Cantor Fitzgerald
3/23/2022$4.00Neutral
B. Riley Securities
More analyst ratings

$RIGL
Press Releases

Fastest customizable press release news feed in the world

See more
  • Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

    SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. (collectively "Annora") resolving patent litigation related to Rigel's product TAVALISSE® (fostamatinib disodium hexahydrate). The litigation resulted from submission by Annora of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of TAVALISSE in the United States. Under the terms of the settlement agreement, Annora will have a license to sell its generic product in Q2 2032 or earli

    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

    SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertise in clinical drug development and translational research, and portfolio strategy.   "We are pleased to have Mark join our Board," said Raul Rodriguez, Rigel's president and CEO. "His experience in clinical development, translational research and portfolio strategy will be a valuable addition to Rigel as we advance our hematology and oncology developm

    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million 2024 total revenue of approximately $179.3 million, which includes TAVALISSE® net product sales of $104.8 million, REZLIDHIA® net product sales of $23.0 million and GAVRETO® net product sales of $17.1 millionR289 granted Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS and Orphan Drug designation for the treatment of MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast sch

    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RIGL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RIGL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RIGL
SEC Filings

See more

$RIGL
Leadership Updates

Live Leadership Updates

See more
  • Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

    SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertise in clinical drug development and translational research, and portfolio strategy.   "We are pleased to have Mark join our Board," said Raul Rodriguez, Rigel's president and CEO. "His experience in clinical development, translational research and portfolio strategy will be a valuable addition to Rigel as we advance our hematology and oncology developm

    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background. "It is a pleasure to welcome Lisa to the team. She brings to Rigel a strong combination of industry leadership experience paired with drug development and regulatory affairs expertise. Her robust hematology and oncology knowledge comp

    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

    STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position

    $CARA
    $IOVA
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$RIGL
Financials

Live finance-specific insights

See more
  • Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million 2024 total revenue of approximately $179.3 million, which includes TAVALISSE® net product sales of $104.8 million, REZLIDHIA® net product sales of $23.0 million and GAVRETO® net product sales of $17.1 millionR289 granted Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS and Orphan Drug designation for the treatment of MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast sch

    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its fourth quarter and full year 2024 financial results after market close on Tuesday, March 4, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of th

    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rigel Provides Business Update and 2025 Outlook

    Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million R289 granted Orphan Drug designation by the FDA for the treatment of MDSRigel anticipates 2025 total revenue of approximately $200 to $210 millionSOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2024, ongoing acti

    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RIGL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more